AI Engines For more Details: Perplexity Kagi Labs You
Diarrhea: Loperamide is most commonly used to treat acute and chronic diarrhea, including traveler's diarrhea and diarrhea associated with inflammatory bowel disease (IBD).
Irritable Bowel Syndrome with Diarrhea (IBS-D): Loperamide may be used to alleviate diarrhea symptoms in individuals with IBS-D, although it does not directly treat the underlying condition.
Gastroenteritis: Loperamide can help reduce the frequency and severity of diarrhea caused by viral or bacterial gastroenteritis.
Colostomy or Ileostomy: Loperamide may be used to regulate bowel movements and reduce diarrhea in individuals with colostomies or ileostomies.
Short Bowel Syndrome: Loperamide may be used to manage diarrhea in individuals with short bowel syndrome, a condition characterized by malabsorption due to surgical removal of a significant portion of the small intestine.
Microscopic Colitis: Loperamide may provide relief from diarrhea symptoms associated with microscopic colitis, a type of inflammatory bowel disease characterized by chronic diarrhea.
Chemotherapy-Induced Diarrhea: Loperamide may be used to manage diarrhea caused by chemotherapy treatments, although its effectiveness in this context may vary.
Radiation-Induced Diarrhea: Loperamide may help alleviate diarrhea associated with radiation therapy to the abdomen or pelvis.
Dumping Syndrome: Loperamide may be used to reduce the frequency of bowel movements and improve symptoms in individuals with dumping syndrome, a condition characterized by rapid gastric emptying and subsequent diarrhea after meals.
Functional Diarrhea: Loperamide may be prescribed to manage chronic functional diarrhea, which is diarrhea without an identifiable organic cause.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | -0.2 | |
Acne | 0.3 | 0.8 | -1.67 |
ADHD | 3.4 | 1.6 | 1.13 |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 1.5 | -1.5 |
Allergic Rhinitis (Hay Fever) | 1.3 | 0.5 | 1.6 |
Allergies | 2.7 | 1.7 | 0.59 |
Allergy to milk products | 1.8 | 0.6 | 2 |
Alopecia (Hair Loss) | 2 | 2 | |
Alzheimer's disease | 2.9 | 6.9 | -1.38 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.7 | 0.8 | 4.88 |
Ankylosing spondylitis | 3.1 | 1.8 | 0.72 |
Anorexia Nervosa | 0.7 | 3 | -3.29 |
Antiphospholipid syndrome (APS) | 1.1 | 1.1 | |
Asthma | 0.6 | 1.3 | -1.17 |
Atherosclerosis | 0.5 | 0.9 | -0.8 |
Atrial fibrillation | 3.1 | 2.4 | 0.29 |
Autism | 7 | 9 | -0.29 |
Barrett esophagus cancer | 0.1 | 0.2 | -1 |
benign prostatic hyperplasia | 0.7 | -0.7 | |
Bipolar Disorder | 1.8 | 1 | 0.8 |
Brain Trauma | 0.9 | 0.9 | 0 |
Breast Cancer | 0.2 | 0.2 | 0 |
Carcinoma | 2.5 | 2 | 0.25 |
Celiac Disease | 2.3 | 3 | -0.3 |
Cerebral Palsy | 0.5 | 1.4 | -1.8 |
Chronic Fatigue Syndrome | 3.4 | 5.7 | -0.68 |
Chronic Kidney Disease | 2 | 2.8 | -0.4 |
Chronic Lyme | 0.7 | -0.7 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.8 | 1.6 | 0.75 |
Chronic Urticaria (Hives) | 0.3 | 1.7 | -4.67 |
Coagulation / Micro clot triggering bacteria | 0.7 | 2 | -1.86 |
Colorectal Cancer | 3.5 | 0.6 | 4.83 |
Constipation | 2.6 | 0.7 | 2.71 |
Coronary artery disease | 1.5 | 1.8 | -0.2 |
COVID-19 | 7.2 | 11.5 | -0.6 |
Crohn's Disease | 6.7 | 8.2 | -0.22 |
cystic fibrosis | 1.5 | -1.5 | |
deep vein thrombosis | 1.7 | -1.7 | |
Depression | 9.7 | 7.6 | 0.28 |
Dermatomyositis | 0.6 | 0.1 | 5 |
Eczema | 0.7 | 1.3 | -0.86 |
Endometriosis | 2 | 0.8 | 1.5 |
Eosinophilic Esophagitis | 0.3 | -0.3 | |
Epilepsy | 3.2 | 3.1 | 0.03 |
erectile dysfunction | 1.2 | 0.5 | 1.4 |
Fibromyalgia | 3.3 | 2.3 | 0.43 |
Functional constipation / chronic idiopathic constipation | 5.8 | 3.4 | 0.71 |
gallstone disease (gsd) | 1.6 | 0.6 | 1.67 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.9 | 0.2 | 8.5 |
Generalized anxiety disorder | 0.8 | 0.7 | 0.14 |
Glioblastoma | 1.6 | -1.6 | |
Gout | 0.7 | -0.7 | |
Graves' disease | 1.1 | 1.7 | -0.55 |
Halitosis | 0.7 | 0.6 | 0.17 |
Hashimoto's thyroiditis | 2.7 | 0.7 | 2.86 |
Hemorrhoidal disease, Hemorrhoids, Piles | 0.2 | 0.2 | |
Hidradenitis Suppurativa | 0.2 | 0.3 | -0.5 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.2 | 0.9 | 1.44 |
hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | 0 |
hyperglycemia | 0.7 | 1.3 | -0.86 |
Hyperlipidemia (High Blood Fats) | 0.2 | 0.1 | 1 |
hypersomnia | 0.2 | 0.5 | -1.5 |
hypertension (High Blood Pressure | 1.6 | 5.4 | -2.38 |
Hypothyroidism | 0.8 | 2.2 | -1.75 |
Hypoxia | 0.9 | 0.9 | |
IgA nephropathy (IgAN) | 0.5 | 4.1 | -7.2 |
Inflammatory Bowel Disease | 3.2 | 6.7 | -1.09 |
Insomnia | 1.1 | 1.7 | -0.55 |
Intelligence | 2.5 | 1 | 1.5 |
Intracranial aneurysms | 2.4 | 0.2 | 11 |
Irritable Bowel Syndrome | 4.3 | 5.2 | -0.21 |
Liver Cirrhosis | 3.9 | 2.6 | 0.5 |
Long COVID | 7.8 | 8 | -0.03 |
Low bone mineral density | 0.3 | 2.1 | -6 |
Lung Cancer | 0.6 | 2 | -2.33 |
ME/CFS with IBS | 0.2 | 1.2 | -5 |
ME/CFS without IBS | 1 | 2 | -1 |
Menopause | 0.7 | 0.7 | |
Metabolic Syndrome | 6 | 8.9 | -0.48 |
Mood Disorders | 10.8 | 7.8 | 0.38 |
multiple chemical sensitivity [MCS] | 0.6 | 0.2 | 2 |
Multiple Sclerosis | 3.5 | 6.6 | -0.89 |
Multiple system atrophy (MSA) | 1.6 | 0.4 | 3 |
myasthenia gravis | 0.2 | 0.2 | |
Neuropathy (all types) | 1.3 | 1.3 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | -0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 3.5 | -2.5 |
NonCeliac Gluten Sensitivity | 0.1 | -0.1 | |
Obesity | 6 | 5.3 | 0.13 |
obsessive-compulsive disorder | 5.4 | 3.9 | 0.38 |
Osteoarthritis | 2 | 0.5 | 3 |
Osteoporosis | 0.8 | 1 | -0.25 |
pancreatic cancer | 0.9 | 0.9 | |
Parkinson's Disease | 2.2 | 4.6 | -1.09 |
Polycystic ovary syndrome | 3.1 | 0.7 | 3.43 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
Premenstrual dysphoric disorder | 0.5 | 0.6 | -0.2 |
primary biliary cholangitis | 0.7 | 1.5 | -1.14 |
Psoriasis | 2.4 | 3.5 | -0.46 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.4 | 3.3 | 0.94 |
Rosacea | 0.6 | 0.4 | 0.5 |
Schizophrenia | 4.7 | 1.3 | 2.62 |
scoliosis | 1.3 | 1.1 | 0.18 |
sensorineural hearing loss | 0.5 | -0.5 | |
Sjögren syndrome | 1.9 | 3.6 | -0.89 |
Sleep Apnea | 1.2 | 1.4 | -0.17 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.1 | 6 |
Stress / posttraumatic stress disorder | 1.7 | 2 | -0.18 |
Systemic Lupus Erythematosus | 3.1 | 2.2 | 0.41 |
Tic Disorder | 1.8 | 0.9 | 1 |
Tourette syndrome | 0.1 | 0.8 | -7 |
Type 1 Diabetes | 3.8 | 2.5 | 0.52 |
Type 2 Diabetes | 6.8 | 6.7 | 0.01 |
Ulcerative colitis | 2.5 | 5.7 | -1.28 |
Unhealthy Ageing | 3.8 | 2.2 | 0.73 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.